浙江昂利康制药股份有限公司 2025 年第三季度报告 证券代码：002940 证券简称：昂利康 公告编号：2025-076 浙江昂利康制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 330,809,619.46 | 20.67% | 1,055,164,597.19 | -5.92% | ...

10月24日，昂利康盘中下跌2.01%，截至10:09，报39.50元/股，成交2.30亿元，换手率3.13%，总市值 79.68亿元。 昂利康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：熊去氧胆酸、维生素、幽 门螺杆概念、宠物经济、高血压防治等。 截至6月30日，昂利康股东户数1.85万，较上期增加50.49%；人均流通股10037股，较上期减少33.55%。 2025年1月-6月，昂利康实现营业收入7.24亿元，同比减少14.52%；归母净利润6592.51万元，同比减少 3.19%。 分红方面，昂利康A股上市后累计派现3.41亿元。近三年，累计派现1.08亿元。 机构持仓方面，截止2025年6月30日，昂利康十大流通股东中，中欧医疗健康混合A（003095）位居第 二大流通股东，持股643.73万股，为新进股东。广发科技创新混合A（008638）位居第三大流通股东， 持股616.06万股，为新进股东。中欧医疗创新股票A（006228）位居第四大流通股东，持股528.25万 股，为新进股东。工银前沿医疗股票A（001717）位居第六大流通股东，持股380.22万股，为新进股 东。富国精 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

上证报中国证券网讯（记者 王墨璞嘉）10月22日，昂利康开盘后迅速封住涨停，报42.81元/股，涨幅达 9.99%。 来源：上海证券报·中国证券网 消息面上，昂利康10月19日公告，公司收到国家药品监督管理局签发的左氧氟沙星片《药品注册证 书》。左氧氟沙星片是氧氟沙星的左旋光学异构体，为第三代喹诺酮类抗菌药，具有抗菌谱广、抗菌作 用强的特点。昂利康表示，左氧氟沙星片获得《药品注册证书》，将进一步丰富公司的产品管线。 ...

Core Viewpoint - The innovative drug sector is experiencing a significant boost, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion (approximately 81.2 billion RMB) [1][3]. Group 1: Market Reaction - On October 22, A-shares and Hong Kong stocks related to innovative drugs surged, with companies like Angli康, 哈三联, and 亚太药业 hitting the daily limit, while药捷安康 saw an increase of over 25% [1][2]. - The biopharmaceutical sector in Hong Kong also experienced substantial gains, with notable increases in stocks such as 轩竹生物 and 信达生物 [2]. Group 2: Strategic Collaboration Details - The collaboration between 信达生物 and 武田制药 aims to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including late-stage candidates IBI363 and IBI343, as well as an early-stage project IBI3001 [2][3]. - 信达生物 will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and has the potential to earn up to $10.2 billion in milestone payments [3]. Group 3: Market Trends and Future Outlook - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [4]. - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [5][6]. - The fourth quarter is expected to see an acceleration in business development (BD) activities, as large international pharmaceutical companies typically allocate their annual budgets during this period [6]. Group 4: Investment Sentiment - Analysts suggest that the current environment is favorable for innovative biotech companies, with increased liquidity and risk appetite in the Hong Kong market [7]. - The focus on innovative drug companies is expected to grow as their core pipelines are validated, while second-tier pipelines are approaching proof-of-concept data [7].

Group 1 - The core viewpoint of the news highlights a significant rise in innovative drug concept stocks, indicating positive market sentiment in this sector [1] Group 2 - Kintor Pharmaceutical saw an increase of over 10% in its stock price [1] - AngliTech experienced a rise of over 8% [1] - Other companies such as Hotgen Biotech, Asia-Pacific Pharmaceutical, and Shuyou Shen also showed upward movement in their stock prices [1]

Core Viewpoint - The innovative drug concept is gaining strength in the market, with notable stocks experiencing significant increases, indicating a positive trend in the pharmaceutical sector [1] Group 1: Stock Performance - Harbin Sanlian and Anglikang both reached the daily limit increase, reflecting strong investor interest [1] - Other companies such as Shutaishen, Asia-Pacific Pharmaceutical, Duori Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiyao also saw price increases, contributing to the overall positive sentiment in the sector [1]

证 券 研 究 报 告 昂利康（002940）重大事项点评 强推（维持） 莱古比星入选 ESMO LBA，平台得到进一步验证 事项： 公司研究 化学制剂 2025 年 10 月 22 日 | 目标价：52.05 | 元 | | --- | --- | | 当前价：38.92 | 元 | 华创证券研究所 证券分析师：郑辰 邮箱：zhengchen@hcyjs.com 执业编号：S0360520110002 公司紧密合作伙伴亲合力的首款创新化疗药物莱古比星 III 期结果入选 ESMO 2025 LBA 并口头汇报。数据整体表现惊艳，呈现疗效和安全性的双优，其肿 瘤微环境特异激活（TMEA)平台机制获得临床级验证。公司深度合作管线的首 款创新药 ALK-N001 依托同一平台路径，后续进展值得关注。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,538 | 1,470 | 1,806 | 2,234 | | 同比增速(%) | ...

昂利康今日下跌6.58%，全天换手率11.37%，成交额8.29亿元，振幅7.70%。龙虎榜数据显示，机构净买 入805.89万元，营业部席位合计净买入557.34万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.34%上榜，机构专用席位净买入805.89万元。 昂利康10月21日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 2497.11 | 793.00 | | 买二 | 机构专用 | 2479.58 | 2319.93 | | 买三 | 中泰证券股份有限公司北京分公司 | 1353.66 | 0.00 | | 买四 | 机构专用 | 1009.49 | 148.93 | | 买五 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 996.42 | 890.13 | | 卖一 | 机构专用 | 2479.58 | 2319.93 | | 卖二 | 机构专用 | 0.00 | 1918.41 | | 卖三 | 东方财富证券股份有限公司拉萨金 ...